Research To Practice | Oncology Videos

Latest Episodes:

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress Sep 25, 2026

Show notes

Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:

Introduction (0:00)
Trials in Progress (1:12)
Chronic Lymphocytic Leukemia (7:09)
Diffuse Large B-Cell Lymphoma (32:35)
Mantle Cell Lymphoma (58:25)
Follicular Lymphoma (1:14:49)

CME information and select publications

HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer Sep 24, 2026

Show notes

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic:

Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann

CME information and select publications

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov (Companion Faculty Lecture) Sep 23, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics:

Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00)
Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20)
DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategies in patients with MM in the second- and later-line settings (9:20)
Monitoring for and management of belamaf-related ocular toxicities (12:29)
Phase I DREAMM-9 trial of belamaf in combination with bortezomib/lenalidomide/dexamethasone (RVd) for transplant-ineligible newly diagnosed MM (16:23)
Ongoing trials evaluating alternative belamaf dosing; practical considerations and recommendations for the administration of belamaf (19:07)

CME information and select publications

Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov Sep 23, 2026

Show notes

Featuring an interview with Dr Douglas W Sborov, including the following topics:

DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)
Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26)
Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36)
Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48)
Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00)
Prevention and management of ophthalmic events related to treatment with belamaf (21:27)
Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49)
Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27)
Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon Sep 22, 2026

Show notes

Featuring perspectives from Dr David W Cescon, including the following topics:

Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)
CNS activity of TROP2-directed antibody-drug conjugates (5:36)
Autoimmune considerations with immunotherapy (10:09)
Treatment of oligoprogressive advanced breast cancer (17:31)

CME information and select publications

Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon Sep 21, 2026

Show notes

Featuring perspectives from Dr David W Cescon, including the following topics:

First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00)
First-line treatment of mTNBC in patients eligible for immunotherapy (12:05)
Adverse events (19:39)

CME information and select publications

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting Sep 17, 2026

Show notes

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:

Introduction (0:00)
Preventing Ovarian Cancer (1:04)
Endometrial Cancer (5:27)
Ovarian Cancer (25:36)
Cervical Cancer (54:04)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 8 Sep 16, 2026

Show notes

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)
Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)
Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)
Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 7 Sep 16, 2026

Show notes

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:

Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)
Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)
Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)
Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)
Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)

CME information and select publications

Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting Sep 15, 2026

Show notes

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics: